142 related articles for article (PubMed ID: 22480849)
1. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.
Nandurdikar RS; Maciag AE; Holland RJ; Cao Z; Shami PJ; Anderson LM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2012 May; 20(9):3094-9. PubMed ID: 22480849
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
[TBL] [Abstract][Full Text] [Related]
4. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
5. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
6. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
7. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.
Chakrapani H; Goodblatt MM; Udupi V; Malaviya S; Shami PJ; Keefer LK; Saavedra JE
Bioorg Med Chem Lett; 2008 Feb; 18(3):950-3. PubMed ID: 18178089
[TBL] [Abstract][Full Text] [Related]
9. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
[TBL] [Abstract][Full Text] [Related]
10. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
[TBL] [Abstract][Full Text] [Related]
11. Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO.
Hutchens S; Manevich Y; He L; Tew KD; Townsend DM
Invest New Drugs; 2011 Oct; 29(5):719-29. PubMed ID: 20232108
[TBL] [Abstract][Full Text] [Related]
12. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
13. Nitroreductase-activated nitric oxide (NO) prodrugs.
Sharma K; Sengupta K; Chakrapani H
Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
Chakrapani H; Wilde TC; Citro ML; Goodblatt MM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2008 Mar; 16(5):2657-64. PubMed ID: 18060792
[TBL] [Abstract][Full Text] [Related]
15. Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "Double JS-K".
Holland RJ; Maciag AE; Kumar V; Shi L; Saavedra JE; Prud'homme RK; Chakrapani H; Keefer LK
Chem Res Toxicol; 2012 Dec; 25(12):2670-7. PubMed ID: 23106594
[TBL] [Abstract][Full Text] [Related]
16. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
17. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.
McMurtry V; Saavedra JE; Nieves-Alicea R; Simeone AM; Keefer LK; Tari AM
Int J Oncol; 2011 Apr; 38(4):963-71. PubMed ID: 21271218
[TBL] [Abstract][Full Text] [Related]
18. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
19. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug.
Findlay VJ; Townsend DM; Saavedra JE; Buzard GS; Citro ML; Keefer LK; Ji X; Tew KD
Mol Pharmacol; 2004 May; 65(5):1070-9. PubMed ID: 15102935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
